MultiCell Technologies Inc. (OTC:MCET) acquired the rights to the Ideal BioStent resorbable coronary stent for an undisclosed amount.
The buyout, via Woonsocket, Rhode Island-based MultiCell’s Xenogenics Corp. subsidiary, also involves the exclusive, worldwide rights to patents covering the technology from Rutgers University.
MultiCell touts the stent as the only one combining two drugs aimed at reducing restenosis — salicylate, aspirin’s active ingredient, and sirolimus. The polymer stent is designed to dissolve completely over the course of a year, according to a press release.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
The device made it through animal and proof-of-concept trials, according to MultiCell chairman and CEO Gerald Newmin.
“We saw a significant opportunity to build upon $20 million in invested capital,” Newmin said in prepared remarks.
MultiCell now owns nearly 92 percent of Xenogenics, after its financing of the Ideal buyout boosted its equity stake in the firm. Xenogenics is developing bioabsorbable stents for the heart and peripheral vasculature.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.